NEWS france‘A race against time’: Sudan struggles with refugee influx from Ethiopia’s Tigray region FRANCIES

An American who had been scheduled to appear as a star witness at the trial in Paris of an Islamic State operative was hospitalized Thursday in the French capital, casting doubt on whether he would still be able to testify about his role in the dramatic capture of the gunman that averted a possible mass slaughter aboard a high-speed train.

site : https://twitter.com/i/events/1331792043585179648

Spencer Stone’s lawyer, Thibault de Montbrial, wouldn’t give details about what is ailing the former U.S. airman, citing medical privacy. He said Stone would not testify as planned on Thursday afternoon.
“I know that he is hospitalized. I don’t know why. I don’t know how he is,” de Montbrial said.
“The only thing I’m certain of is that he is not in a state to testify today. We are going to regroup this evening to gauge whether he can be heard tomorrow morning or afternoon.”
Stone, then a 23-year-old, was among passengers who helped subdue gunman Ayoub El Khazzani aboard the Amsterdam to Paris train in 2015.
Their heroics during the drama on Aug. 21, 2015, inspired Clint Eastwood to direct a Hollywood re-enactment: “The 15:17 to Paris.”

site : https://twitter.com/i/events/1331793023139778560

El Khazzani, a 31-year-old Moroccan, is on trial with three suspected accomplices. He risks life in prison if convicted of attempted terrorist murder.
El Khazzani boarded the train in Brussels armed with a Kalashnikov, nine clips with 30 rounds each, an automatic pistol and a cutter, according to investigators. Once aboard the train, El Khazzani lingered in a restroom between cars and then emerged bare-chested with his weapons.
One of the witnesses scheduled to testify on Thursday afternoon is Mark Moogalian, a French-American who wrestled the Kalashnikov off El Khazzani — before being shot himself by a pistol.
Stone has said he was coming out of a deep sleep when the gunman appeared. He and Alek Skarlatos, then a 22-year-old U.S. National Guardsman recently back from Afghanistan, snapped into action, tackling the gunman.
Stone, whose hand was injured by the cutter, is also credited with saving Moogalian, whose neck was squirting blood.
Pour l’un, c’est 94,5 % d’efficacité ; pour l’autre, c’est 90 %. Aux yeux du grand public, seuls ces deux chiffres comptent tant ils sont porteurs d’espoir dans la lutte contre le Covid-19. Mais pour la recherche médicale, les très prometteurs candidats-vaccins de la société américaine Moderna et de BioNTech, la start-up allemande associée au géant américain Pfizer, représentent aussi une percée majeure pour une technologie jugée prometteuse depuis longtemps mais qui n’a encore jamais prouvé son efficacité chez les humains.
La pire crise sanitaire depuis plus d’un siècle pourrait devenir le baptême du feu des thérapies à base d’ARN messager (ARNm) synthétique. C’est cette technique, en développement depuis les années 1970 sous l’impulsion de la chercheuse d’origine hongroise Katalin Karikó, qui a été utilisée par Moderna et BioNTech/Pfizer pour mettre au point leurs réponses au Covid-19.